Navigation Links
Webcast Alert: MicroRNA: The Year in Review

CARLSBAD, Calif., Dec. 9 /PRNewswire/ -- Regulus Therapeutics Inc. will host an educational Webinar featuring a discussion with leading microRNA scientists: Tom Tuschl, Ph.D. Professor at Rockefeller University and Markus Stoffel, M.D., Ph.D. Professor at the Swiss Federal Institute of Technology. Dr. Tuschl will discuss the discovery of microRNA and its role as a master regulator of the genome, and Dr. Stoffel will discuss the elucidation of microRNA function in normal and disease states, and therapeutic strategies based on microRNA modulation.

What:      MicroRNA: The Year in Review

When:      3 p.m. EST on Monday, December 14


How:       Live over the Internet -- Simply log on at the address above.


                      Regulus Therapeutics
                      Garry E. Menzel, Ph.D.

                      Heidi Chokeir, Ph.D.
                      Russo Partners, LLC

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery of innovative new medicines based on microRNAs. Regulus is targeting microRNAs as a new class of therapeutics by working with a broad network of academic collaborators and leveraging oligonucleotide drug discovery and development expertise from Alnylam Pharmaceuticals and Isis Pharmaceuticals (Alnylam and Isis jointly formed Regulus in 2007). Regulus is advancing microRNA therapeutics towards the clinic in several areas including hepatitis C infection, cardiovascular disease and fibrosis, oncology, and immunology and inflammation. Regulus intellectual property estate contains both the fundamental and core patents in the field as well as over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNAs for therapeutic applications. In 2008, Regulus entered into a major alliance with GlaxoSmithKline to discover and develop microRNA therapeutics for immuno-inflammatory diseases. For more information, visit

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from and at least a 56Kbps connection to the Internet.

If you experience problems listening to the webcast, send an E-mail to:

SOURCE Regulus Therapeutics Inc.

SOURCE Regulus Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
2. Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications
3. Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today
4. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
5. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
6. Sunrise to Host Conference Call and Webcast to Discuss Third-Quarter 2009 Financial Results
7. Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday, November 4, at 10 A.M. EST
8. NHP Announces Third Quarter Earnings Release Date and Webcast/Conference Call
9. Smart Balance to Host Webcast/Conference Call on 2009 Third-Quarter Results
10. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results
11. CBIZ Webcasts Third-Quarter 2009 Conference Call
Post Your Comments:
(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical ... more about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared ... thicker and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... ... Dental professionals who would like to become more proficient on their knowledge of ... Advanced Implant Mentoring (AIM) CE course. Courses will be held on December 3rd, 4th ... Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce that individuals ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
(Date:11/26/2015)... 26, 2015 --> ... approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... found that immunotherapy can be efficiently combined with photodynamic ...
Breaking Medicine Technology: